An update on novel pharmacological agents for primary sclerosing cholangitis
- 2 January 2022
- journal article
- other
- Published by Taylor & Francis in Expert Opinion on Therapeutic Targets
- Vol. 26 (1) , 69-77
Abstract
: Primary sclerosing cholangitis (PSC) is a rare chronic cholestatic liver disease with heterogeneous phenotypes that may lead to liver transplantation and/or end-stage liver disease. Its multifact...Keywords
This publication has 70 references indexed in Scilit:
- Pathogenesis of Primary Sclerosing Cholangitis and Advances in Diagnosis and ManagementGastroenterology, 2013
- Ursodeoxycholic acid stabilizes the bile salt export pump in the apical membrane in MDCK II cellsJournal of Gastroenterology, 2013
- Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitisNature Genetics, 2013
- Retinoic acid represses CYP7A1 expression in human hepatocytes and HepG2 cells by FXR/RXR-dependent and independent mechanismsJournal of Lipid Research, 2010
- Bezafibrate for the treatment of primary sclerosing cholangitisJournal of Gastroenterology, 2010
- High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis #Hepatology, 2009
- Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2 −/− mice†‡§Hepatology, 2009
- Functional and comparative metagenomic analysis of bile salt hydrolase activity in the human gut microbiomeProceedings of the National Academy of Sciences, 2008
- Overlap syndromes among autoimmune liver diseasesWorld Journal of Gastroenterology, 2008
- Bile Salt Hydrolase Activity in ProbioticsApplied and Environmental Microbiology, 2006